OptimizeRx Corp's sales fell 17% last year in Q3, bringing in $21.6 million.

Nov 13, 2026, 4:10 PM ETResultsRead the original at SEC EDGAR

Neutral

OptimizeRx's Q3 sales fell 17%, and contracted sales were below last year's pace, leading it to update its 2026 sales forecast. Higher profit, debt repayment, and reported growth in 2027 contracted sales balance the weakness, so the report does not clearly shift its outlook.

OPRX · OptimizeRx Corp

AI read · Neutral

The AI's read

The weaker sales and lower average sales from its 20 largest drug-company customers point to softer spending. Higher net income, stronger adjusted EBITDA, and debt repayment show improved profits and less debt. The company says contracted sales for 2027 are growing and demand may be building. Those are signs it expects, not completed sales, so they do not settle the mixed report.

Get alerts for OPRX

Follow OptimizeRx Corp (OPRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OPRX

Free on the App Store and Google Play, or on the web.